By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Global Blood Therapeutics 

400 E. Jamie Court
Suite 101
South San Francisco  California  94080  U.S.A.
Phone: 650-741-7700 Fax: n/a


Global Blood Therapeutics is developing novel, orally-available therapeutics designed to change the treatment paradigm for chronic blood diseases. The Company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options.

The current standard of care treats the symptoms during acute episodes; however, the underlying pathology of the disease causes progressive damage to the body. Global Blood Therapeutics is focused on the critical need for therapeutics that address the causes of blood diseases, not just the symptoms.

Global Blood Therapeutics’ extensive drug discovery capabilities — combining world-class medicinal chemistry with deep expertise in blood biology — are driving its product pipeline of mechanism-based therapeutics.

The Company has built a pipeline of preclinical programs focused on several blood diseases. Its lead program is in sickle cell disease, a global health challenge with very limited treatment options and none that address the underlying cause of the disease. The Company’s pipeline also includes a novel therapeutic for hereditary angioedema.

Global Blood Therapeutics is a private Company led by an experienced management team with a track record of four successful drug approvals and more than 30 investigational new drug applications. Backed by Third Rock Ventures, the Company was founded in 2012 with a $40.7 million Series A financing.

Key Statistics

Ownership: Public

Web Site: Global Blood Therapeutics
Employees: n/a
Symbol: GBT


Company News
Bay Area's Global Blood Therapeutics (GBT) and the FDA Finally Reach Agreement on Trial Design for Sickle Cell Disease Drug 10/25/2016 5:53:18 AM
Global Blood Therapeutics (GBT) Announces Appointment Of Tricia Suvari As Chief Legal Officer 10/12/2016 8:26:01 AM
Global Blood Therapeutics (GBT) Presents GBT440 Data That Continue To Support Durability, Safety And Mechanism Of Action In Sickle Cell Disease 10/7/2016 9:35:57 AM
Global Blood Therapeutics (GBT) Announces Publication Of Preclinical Results Supporting GBT440 Program For Hypoxemic Pulmonary Disorders 9/15/2016 9:00:36 AM
Global Blood Therapeutics (GBT) Joins Sickle Cell Disease (SCD) Coalition In Support Of SCD Community With Goal To Improve Treatment And Care 9/6/2016 8:45:07 AM
Global Blood Therapeutics (GBT) Announces Participation At Two Upcoming Investor Conferences In September 9/1/2016 8:35:34 AM
Global Blood Therapeutics (GBT) To Present At The Wedbush PacGrow Healthcare Conference 8/10/2016 11:19:27 AM
Global Blood Therapeutics (GBT) Announces Publication Of Preclinical GBT440 Results In British Journal Of Haematology That Support Sickle Cell Disease (SCD) Program 7/8/2016 7:27:35 AM
Global Blood Therapeutics (GBT) Announces Initiation Of Phase 2a Study Of GBT440 In Adolescents With Sickle Cell Disease 6/30/2016 6:07:34 AM
Global Blood Therapeutics (GBT) Announces Closing Of Public Offering Of Common Stock 6/27/2016 8:25:22 AM